Leuven (BELGIUM) - 10 September, 2015 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, will announce its half-year results for 2015 on Tuesday 15 September 2015 at 17:45 CET.
TiGenix CEO, Eduardo Bravo, and CFO, Claudia D’Augusta, will host a conference call and webcast during which the half-year results for 2015 will be presented, followed by a Q&A session. This event will be held on Tuesday 15 September 2015 at 18.45 CET/12.45 pm EDT.
Please dial one of the following numbers to participate:
London, United Kingdom: +44(0)20 3427 1905 New York, USA: +1646 254 3361 Paris, France: +33(0)1 76 77 22 27 Brussels, Belgium: +32(0)2 620 0138 Madrid, Spain: +3491 114 6583 Montreal, Canada: +1514 841 2154 Amsterdam, Netherlands: +31(0)20 716 8256 Stockholm, Sweden: +46(0)8 5033 6538
Confirmation Code: 9894390
The webcast can be followed live online via the link: http://edge.media-server.com/m/p/g4kvinkh
The press release and the webcast slide presentation will be made available in the Newsroom section of the TiGenix website. A replay of the webcast will be available on the website shortly after the live webcast has finished.
For more information
Claudia D’Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com
Ana Pombo
Strategic Planning and IR Manager
T: + 34 91 804 92 64
ana.pombo@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. Cx611 has completed a Phase I/II trial in rheumatoid arthritis, as well as a Phase I sepsis challenge trial. Effective as of July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product (AlloCSC-01) is currently in a Phase II clinical trial in acute myocardial infarction (AMI). Coretherapix is planning to initiate the clinical evaluation of AlloCSC-01 in the chronic setting as well and is also involved in the pre-clinical development of a pharmaceutical formulation of growth factors to treat AMI. Finally, TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect were exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain).
For more information, please visit www.tigenix.com
Help employers find you! Check out all the jobs and post your resume.
